7 completed, 5 unknown, 2 active not recruiting, 2 recruiting. 16 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 7, Unknown 5, Active not recruiting 2, Recruiting 2 |
| Phase 2 | 3 | Unknown 2, Completed 1 |
Follow Safety: new trials by email Literature Review of Safety trials Research Report on Safety
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC MVA-BN standard regimen, MVA-BN standard regimen (Administered as PEP) - Neonate, Maternal Transmission | Phase 3 | Active not recruiting | Jean-Pierre Van geertruyden | 359 | 2025-06-23 | 2026-01-30 |
| Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC MVA-BN standard regimen, MVA-BN half-dose regimen - Mpox (Monkeypox), Vaccination | Phase 3 | Active not recruiting | Jean-Pierre Van geertruyden | 344 | 2025-05-29 | 2026-04-29 |
| Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer AK104 - Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody) | Phase 3 | Recruiting | Anhui Provincial Hospital | 100 | 2025-03-11 | 2026-10-28 |
| Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer Fluzoparib, Apatinib Mesylate - Epithelial Ovarian Cancer, Efficacy | Phase 3 | Unknown | Anhui Provincial Hospital | 51 | 2024-10-01 | 2024-08-06 |
| A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2 Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2; - Immunogenicity, Safety | Phase 2 / Phase 3 | Unknown | Stemirna Therapeutics | 800 | 2023-06-20 | 2023-06-20 |
| PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study PyloPlus Urea Breath Test System, Stool Antigen Test - Helicobacter Pylori, Safety | Phase 3 | Recruiting | ARJ Medical, Inc. | 40 | 2022-11-17 | 2023-05-06 |
| mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs SW-BIC-213;SARS-Cov-2., Sinopharm (BIBP);SARS-Cov-2., Pfizer(BNT162b2);SARS-Cov-2. - Immunogenicity, Safety | Phase 3 | Unknown | Stemirna Therapeutics | 600 | 2022-10-19 | 2023-01-17 |
| New Generation mRNA Booster Vaccine Against Emerging VOCs SW-BIC-213, SARS-Cov-2 Vaccina(Vero Cell ) Inactivated - Immunogenicity, Efficacy | Phase 3 | Unknown | Stemirna Therapeutics | 2000 | 2022-10-01 | 2023-04-12 |
| Study to Compare PK & Safety of Advixa With Humira in Healthy, Adult Subject Followed by Efficacy & Safety Study in RA Patients Advixa (Adalimumab) - Pharmacokinetics, Safety | Phase 2 / Phase 3 | Unknown | Institute for Developing Science and Health Initiatives, Bangladesh | 200 | 2021-06-02 | 2022-07-07 |
| Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents E4/DRSP 15/3 mg combined tablet - Safety | Phase 3 | Completed | Estetra | 145 | 2020-12-28 | 2023-12-22 |
| Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B Recombinant Hepatitis B + DTP-HB-Hib, Hep B + Pentabio (registered) - Immunogenicity, Safety | Phase 3 | Completed | PT Bio Farma | 220 | 2020-10-13 | 2022-01-18 |
| Renoir: A Randomised, Double-blind, Controlled Trial to Evaluate the Effects of a New Human Milk Fortifier on Growth and Tolerance in Preterm Infants. Test product, Control product - Subjects in Need of a Human Milk Fortifier (HMF), Growth | Phase 2 / Phase 3 | Completed | Nutricia Research | 207 | 2018-03-08 | 2024-09-26 |
| Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age ATX-101, Placebo - Moderate to Severe Convexity of Submental Fat, Safety | Phase 3 | Completed | Kythera Biopharmaceuticals | 55 | 2014-04-01 | 2020-02-17 |
| Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat Deoxycholic Acid, Placebo - Moderate to Severe Convexity of Submental Fat, Safety | Phase 3 | Completed | Kythera Biopharmaceuticals | 93 | 2014-01-01 | 2020-02-17 |
| Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil and hydrochlorothiazide - Safety | Phase 3 | Completed | Takeda | 153 | 2011-03-01 | 2013-12-13 |
| Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose. 13-valent pneumococcal conjugate vaccine - 13-valent Pneumococcal Vaccine, Immunization | Phase 3 | Completed | Pfizer | 263 | 2010-04-01 | 2012-02-08 |
Mpox, Monkeypox (2) · Smallpox (2) · Arthritis, Rheumatoid (1) · Carcinoma, Ovarian Epithelial (1) · Hypertension (1) · Kidney Diseases (1) · Renal Insufficiency (1)
Animal Diseases (2) · DNA Virus Infections (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Infections (2) · Poxviridae Infections (2) · Primate Diseases (2) · Rodent Diseases (2) · Urogenital Diseases (2) · Virus Diseases (2) · Adnexal Diseases (1) · Arthritis (1) · Autoimmune Diseases (1) · Carcinoma (1) · Cardiovascular Diseases (1)
Deoxycholic Acid (2) · Adalimumab (1) · Chlorthalidone (1) · Control Groups (1) · Hydrochlorothiazide (1) · Olmesartan Medoxomil (1) · apatinib (1) · azilsartan medoxomil (1) · fluzoparib (1)
Stemirna Therapeutics (3) · Anhui Provincial Hospital (2) · Jean-Pierre Van geertruyden (2) · Kythera Biopharmaceuticals (2) · ARJ Medical, Inc. (1) · Estetra (1) · Institute for Developing Science and Health Initiatives, Bangladesh (1) · Nutricia Research (1) · PT Bio Farma (1) · Pfizer (1) · Takeda (1)
United States (3) · Democratic Republic of the Congo (2) · France (2) · Germany (2) · Laos (2) · Latvia (2) · Netherlands (2) · Poland (2) · Bangladesh (1) · Bulgaria (1) · China (1) · Estonia (1) · Finland (1) · Georgia (1) · Indonesia (1)
Mayfong Mayxay, doctor (3) · Frederick Beddingfield, III, MD, PhD (2) · Eddy Fadliyana (1) · Ying Zhou, MD (1) · Zannat Kawser, M.Phil. (1)
PMID 29504252, PMID 38169790, PMID 40037774, PMID 42372625, PMID 42521300
2019 (1)